Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CORT Corcept Therapeutics	$72.65 +1.8%	$72.87	$29.42 ▼ $117.33	$7.66B	0.15	1.18 million shs	675,773 shs
CYDY CytoDyn	$0.29 +5.6%	$0.34	$0.10 ▼ $0.49	$356.69M	1.17	1.38 million shs	413,710 shs
DRNA Dicerna Pharmaceuticals	$38.22	$38.12	$19.06 ▼ $40.14	$2.99B	0.8	1.34 million shs	N/A
PCRX Pacira BioSciences	$23.21 0.0%	$25.17	$11.16 ▼ $27.64	$1.07B	0.48	915,165 shs	202,316 shs
SAGE Sage Therapeutics	$9.20 +1.3%	$7.53	$4.62 ▼ $13.47	$576.11M	0.29	1.30 million shs	3.01 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CORT Corcept Therapeutics	0.00%	-0.78%	+3.82%	-2.42%	+138.20%
CYDY CytoDyn	0.00%	+10.68%	-17.99%	+35.07%	+109.87%
DRNA Dicerna Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
PCRX Pacira BioSciences	0.00%	-1.17%	-13.99%	+0.45%	+7.13%
SAGE Sage Therapeutics	0.00%	+0.49%	+40.60%	+34.04%	-13.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CORT Corcept Therapeutics	4.7153 of 5 stars	3.5	1.0	0.0	4.3	2.7	4.2	1.9
CYDY CytoDyn	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DRNA Dicerna Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PCRX Pacira BioSciences	3.457 of 5 stars	2.2	2.0	0.0	3.9	2.2	2.5	0.6
SAGE Sage Therapeutics	3.2341 of 5 stars	2.0	2.0	0.0	4.1	2.3	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CORT Corcept Therapeutics	3.00	Buy	$138.25	90.30% Upside
CYDY CytoDyn	0.00	N/A	N/A	N/A
DRNA Dicerna Pharmaceuticals	0.00	N/A	N/A	N/A
PCRX Pacira BioSciences	2.33	Hold	$26.44	13.96% Upside
SAGE Sage Therapeutics	2.00	Hold	$8.93	-2.85% Downside

Current Analyst Ratings Breakdown

Latest PCRX, CORT, SAGE, CYDY, and DRNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	SAGE Sage Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$7.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$9.00 ➝ $8.50
6/17/2025	SAGE Sage Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Hold ➝ Hold	$8.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$12.00
6/17/2025	SAGE Sage Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$8.00 ➝ $8.50
6/16/2025	SAGE Sage Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/9/2025	PCRX Pacira BioSciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $30.00
5/6/2025	CORT Corcept Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$135.00
5/6/2025	CORT Corcept Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$150.00 ➝ $145.00
4/25/2025	SAGE Sage Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/8/2025	PCRX Pacira BioSciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00

(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CORT Corcept Therapeutics	$675.04M	11.41	$1.25 per share	58.19	$6.49 per share	11.19
CYDY CytoDyn	N/A	N/A	N/A	N/A	($0.11) per share	N/A
DRNA Dicerna Pharmaceuticals	$164.31M	18.17	N/A	N/A	$1.84 per share	20.77
PCRX Pacira BioSciences	$700.97M	1.53	$4.31 per share	5.38	$16.86 per share	1.38
SAGE Sage Therapeutics	$41.24M	13.96	N/A	N/A	$7.60 per share	1.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CORT Corcept Therapeutics	$141.21M	$1.16	62.63	39.27	N/A	19.33%	20.40%	16.64%	8/4/2025 (Estimated)
CYDY CytoDyn	-$49.84M	N/A	0.00	∞	N/A	N/A	N/A	-33.26%	8/14/2025 (Estimated)
DRNA Dicerna Pharmaceuticals	-$112.75M	-$1.63	N/A	N/A	N/A	-64.53%	-103.08%	-16.58%	N/A
PCRX Pacira BioSciences	-$99.56M	-$2.28	N/A	9.03	N/A	-14.78%	13.78%	7.00%	7/29/2025 (Estimated)
SAGE Sage Therapeutics	-$400.67M	-$5.80	N/A	N/A	N/A	-747.63%	-68.99%	-60.67%	7/30/2025 (Estimated)

Latest PCRX, CORT, SAGE, CYDY, and DRNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/30/2025	Q2 2025	SAGE Sage Therapeutics	-$0.96	N/A	N/A	N/A	$16.69 million	N/A
7/29/2025	Q2 2025	PCRX Pacira BioSciences	$0.73	N/A	N/A	N/A	$183.11 million	N/A
5/5/2025	Q1 2025	CORT Corcept Therapeutics	$0.17	$0.17	N/A	$0.17	$177.93 million	$157.21 million
4/29/2025	Q1 2025	SAGE Sage Therapeutics	-$0.99	-$1.01	-$0.02	-$1.01	$14.12 million	$14.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CORT Corcept Therapeutics	N/A	N/A	N/A	N/A	N/A
CYDY CytoDyn	N/A	N/A	N/A	N/A	N/A
DRNA Dicerna Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PCRX Pacira BioSciences	N/A	N/A	N/A	N/A	N/A
SAGE Sage Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CORT Corcept Therapeutics	N/A	3.07	2.96
CYDY CytoDyn	N/A	0.30	0.30
DRNA Dicerna Pharmaceuticals	N/A	2.46	2.46
PCRX Pacira BioSciences	0.48	2.41	1.99
SAGE Sage Therapeutics	N/A	9.13	9.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CORT Corcept Therapeutics	93.61%
CYDY CytoDyn	5.06%
DRNA Dicerna Pharmaceuticals	78.91%
PCRX Pacira BioSciences	99.73%
SAGE Sage Therapeutics	99.22%

Insider Ownership

Company	Insider Ownership
CORT Corcept Therapeutics	20.80%
CYDY CytoDyn	0.54%
DRNA Dicerna Pharmaceuticals	10.20%
PCRX Pacira BioSciences	6.40%
SAGE Sage Therapeutics	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CORT Corcept Therapeutics	300	106.04 million	83.99 million	Optionable
CYDY CytoDyn	20	1.25 billion	1.24 billion	Not Optionable
DRNA Dicerna Pharmaceuticals	302	78.13 million	70.16 million	Optionable
PCRX Pacira BioSciences	720	46.29 million	43.33 million	Optionable
SAGE Sage Therapeutics	690	62.62 million	59.18 million	Optionable

PCRX, CORT, SAGE, CYDY, and DRNA Headlines

Recent News About These Companies

Sage Therapeutics (NASDAQ:SAGE) Share Price Passes Above Two Hundred Day Moving Average - Here's Why

July 4 at 5:17 AM | marketbeat.com

Sage Therapeutics (NASDAQ:SAGE) Shares Pass Above 50 Day Moving Average - Here's Why

July 4 at 5:17 AM | marketbeat.com

Rx Rundown: AbbVie, Healthline, Beckley Psytech and more

July 3 at 4:51 PM | mmm-online.comM

Sage’s Search for Lifeline Ran Into Defiant Biogen CEO

July 3 at 4:51 PM | biospace.comB

M&A ramped up in June, with blueBird, Sage and Snyk tie-ups

July 2 at 11:18 PM | bizjournals.com

Boston-area pharma company to lay off entire 300-person staff after sale

July 1, 2025 | msn.com

$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Sage Therapeutics, Inc. (NASDAQ: SAGE)

July 1, 2025 | globenewswire.com

What Makes Sage Therapeutics (SAGE) a New Buy Stock

July 1, 2025 | zacks.com

Sage Therapeutics cuts most of its workforce following acquisition

July 1, 2025 | statnews.comS

Sage lays off entire staff of 338 amid takeover by Supernus

July 1, 2025 | fiercepharma.comF

This common kitchen herb ingredient could help target or slow Alzheimer’s

June 29, 2025 | msn.com

Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms

June 23, 2025 | msn.com

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

June 23, 2025 | globenewswire.com

Sage Therapeutics price target lowered to $8.50 from $11 at JPMorgan

June 22, 2025 | msn.com

Sage Therapeutics (NASDAQ:SAGE) Given New $9.00 Price Target at Robert W. Baird

June 20, 2025 | marketbeat.com

Rx Rundown: Sanofi, Processa Pharmaceuticals, Eli Lilly and more

June 20, 2025 | mmm-online.comM

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

June 18, 2025 | businesswire.com

Another Gene Therapy Death; Biopharma M&A Picks Up; a Vaccine Board of Vaccine Skeptics

June 18, 2025 | biospace.comB

SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal

June 17, 2025 | zacks.com

Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock?

June 17, 2025 | zacks.com

Sage Therapeutics (NASDAQ:SAGE) Earns Neutral Rating from Piper Sandler

June 17, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCRX, CORT, SAGE, CYDY, and DRNA Company Descriptions

Corcept Therapeutics NASDAQ:CORT

$72.65 +1.31 (+1.84%)

Closing price 07/3/2025 03:28 PM Eastern

Extended Trading

$72.65 0.00 (0.00%)

As of 07/3/2025 04:20 PM Eastern

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

CytoDyn OTCMKTS:CYDY

$0.29 +0.02 (+5.56%)

As of 07/3/2025 12:59 PM Eastern

CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

Dicerna Pharmaceuticals NASDAQ:DRNA

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.

Pacira BioSciences NASDAQ:PCRX

$23.20 -0.01 (-0.02%)

As of 07/3/2025 01:23 PM Eastern

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Sage Therapeutics NASDAQ:SAGE

$9.20 +0.12 (+1.27%)

Closing price 07/3/2025 02:52 PM Eastern

Extended Trading

$9.20 0.00 (0.00%)

As of 07/3/2025 04:28 PM Eastern

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time